Loading
Crispr-cas9 / Gene Editing / Crispr-cas Systems · Journal article
Virulence · July 14, 2026
Raises a question worth testing. It does not answer one.
This is a proof-of-concept mechanistic study demonstrating that rcnB disruption in A. baumannii AB5075 enhances colistin susceptibility through multiple cellular pathways including membrane integrity compromise, oxidative stress impairment, and reduced efflux pump activity. The work identifies rcnB as a potential contributor to colistin resistance but remains exploratory and requires validation in clinical isolates and animal models before informing therapeutic strategies.
Targeted gene disruption study with complementation in a reference bacterial strain. A. baumannii AB5075, a multidrug-resistant clinical isolate; no information on clinical sample source, setting, or patient characteristics provided. Intervention: Disruption of rcnB gene via CRISPR-Cas9-mediated deletion; AB5075 ΔrcnB mutant strain. Compared with: Wild-type AB5075 (AB5075 WT) and complemented strain (AB5075 ΔrcnB::rcnB).
Loss of rcnB markedly potentiated colistin-mediated killing in AB5075 ΔrcnB mutant rcnB deletion resulted in compromised membrane integrity, impaired oxidative stress defenses, and reduced efflux pump activity Transcriptomic profiling revealed rcnB deletion reshaped stress-response networks including suppression of fatty acid biosynthesis and ROS-detoxifying pathways
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This mechanistic finding does not establish clinical utility and should not be used to guide treatment decisions. The work provides a potential molecular target for future drug development but requires validation across multiple clinical isolates and in vivo models before therapeutic strategies can be designed.
Mechanistic in vitro study using CRISPR-Cas9 gene editing to explore rcnB function in a single bacterial strain; raises questions about colistin resistance mechanisms rather than establishing clinical evidence.
As stated by the source record.
This mechanistic finding does not establish clinical utility and should not be used to guide treatment decisions. The work provides a potential molecular target for future drug development but requires validation across multiple clinical isolates and in vivo models before therapeutic strategies can be designed.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Acinetobacter baumannii AB5075 is a clinically relevant multidrug-resistant (MDR) isolate that poses a major therapeutic challenge. Although colistin has been reinstated as a last-resort antibiotic against MDR Gram-negative infections, the rapid emergence of colistin resistance threatens its clinical utility. Here, we employed a CRISPR-Cas9-based genome editing system to generate an A. baumannii AB5075 ΔrcnB mutant and uncovered a previously underappreciated role of rcnB in modulating colistin susceptibility. Loss of rcnB markedly potentiated colistin-mediated killing through multiple associated changes, including compromised membrane integrity, impaired oxidative stress defenses, and reduced efflux pump activity. Transcriptomic profiling further revealed that rcnB deletion reshaped global stress-response networks, including suppression of fatty acid biosynthesis and reactive oxygen species (ROS)-detoxifying pathways, alongside altered metal ion and sulfur metabolism during colistin exposure. Collectively, our findings suggest that rcnB may contribute to colistin susceptibility of colistin resistance and provide mechanistic insights that may inform the development of targeted strategies to enhance colistin efficacy against MDR A. baumannii.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.